Compare Baxter International Inc (BAX) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Baxter International Inc vs BIO-TECHNE Corp — how do they compare? Baxter International Inc trades at $22.35 (market cap $11.26B), while BIO-TECHNE Corp trades at $71.42 (market cap $11.10B). The key difference: Baxter International Inc and BIO-TECHNE Corp are close in size by market cap, and Baxter International Inc pays the higher dividend (0.92%). Which is the better fit depends on your goals.
| BAX | TECH | |
|---|---|---|
Market Cap | $11.26B | $11.10B |
Sector | Health | Health |
52-Week High | $29.22 | $71.38 |
52-Week Low | $15.80 | $43.31 |
Enterprise Value | $18.93B | $11.18B |
Dividend Yield | 0.92% | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Baxter International (BAX) trades at $22.57, down 0.22% on the day, with mixed technical signals showing a bullish moving average trend but neutral oscillators. The company reported Q1 2026 earnings beat with $0.36 EPS versus $0.31 expected, though net income margin remains negative at -9.7%. Recent news highlights upcoming Q2 earnings call and sustainability initiatives, while analyst consensus sits at $22.67 price target with 42% buy ratings.
BAX faces fundamental challenges with negative profitability metrics and volatile cash flow, but valuation appears reasonable with P/S of 1.02. The stock offers potential upside to analyst targets if operational improvements materialize, though investors must weigh high debt levels and inconsistent earnings performance against turnaround prospects in the medical technology sector.
Bio-Techne (TECH) trades at $71.36, showing minimal daily movement (+0.08%) as the market digests Merck KGaA's $73 per share acquisition offer. The stock sits just 2.3% below the buyout price, with technical indicators showing bullish momentum. Fundamentally, the company maintains strong gross margins (64.96%) but faces declining net income margins (6.01% in 2025). Recent earnings show mixed results with one beat and two misses in the last four quarters.
The acquisition premium provides near-term upside potential, though shareholder litigation risks exist regarding deal fairness. Long-term investors face uncertainty about post-acquisition prospects, while current valuation metrics (P/E 101.94) appear stretched without the takeover scenario. The $73 offer price represents the primary catalyst, with downside risk to $50 if the deal fails.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Baxter International Inc
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
